Ascendis Pharma A/S

15 clinical trials · Sponsor

Record	Firm	Date
A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism (NCT07706764)	Ascendis Pharma A/S	2026-04-22
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding (NCT07345494)	Ascendis Pharma A/S	2026-02-18
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders (NCT07221851)	Ascendis Pharma A/S	2025-12-12
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia. (NCT06732895)	Ascendis Pharma A/S	2024-12-10
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia (NCT06079398)	Ascendis Pharma A/S	2024-01-23
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (NCT05980598)	Ascendis Pharma A/S	2023-09-29
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia (NCT04085523)	Ascendis Pharma A/S	2020-06-24
A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism (NCT04009291)	Ascendis Pharma A/S	2019-08-27
A Multi-center, Longitudinal, Observational Study of Children With Achondroplasia (NCT03875534)	Ascendis Pharma A/S	2019-06-19
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial (NCT03344458)	Ascendis Pharma A/S	2017-12-19

Track Ascendis Pharma A/S automatically

Every clearance here is in the API, with alerts when new ones post.